Baidu
map

Arch Gen Psychiatry:晚年抑郁症可能预示阿尔茨海默氏症

2012-05-10 Beyond 生物谷

5月7日,发生在中年和晚年的抑郁症症状与血管性痴呆的风险增加有关,而在晚年生活中出现的症状更可能是阿尔茨海默氏症的早期征兆,根据美国加州大学旧金山的Kaiser Permanente研究人员完成的一项研究证实。 这项研究结果刊登在本期的Archives of General Psychiatry杂志上,是首次检查无论是中年或晚年抑郁症是否更容易导致长期阿尔茨海默氏症或血管性痴呆。研究人员解释说,

5月7日,发生在中年和晚年的抑郁症症状与血管性痴呆的风险增加有关,而在晚年生活中出现的症状更可能是阿尔茨海默氏症的早期征兆,根据美国加州大学旧金山的Kaiser Permanente研究人员完成的一项研究证实。

这项研究结果刊登在本期的Archives of General Psychiatry杂志上,是首次检查无论是中年或晚年抑郁症是否更容易导致长期阿尔茨海默氏症或血管性痴呆。研究人员解释说,血管性痴呆是第二、中最常见的痴呆类型,部分脑血流受损导致细胞失去营养和氧气。

加州大学旧金山分校精神病学和流行病学与生物统计学和旧金山退伍军人事务医疗中心的部门公共卫生硕士Deborah E. Barnes博士说:那些在中年和晚年抑郁症状的人更容易发展血管性痴呆。

研究人员表示:虽然更多的研究是需要的,但调查结果表明抑郁症在晚年开始可能是阿尔茨海默氏病的早期症状,慢性抑郁症可能会反映大脑血流量的长期变化过程以及血管性痴呆风险的增加。 

 

doi:10.1001/archgenpsychiatry.2011.1481
PMC:
PMID:

Midlife vs Late-Life Depressive Symptoms and Risk of Dementia

Deborah E. Barnes, PhD, MPH; Kristine Yaffe, MD; Amy L. Byers, PhD, MPH; Mark McCormick, MD; Catherine Schaefer, MD; Rachel A. Whitmer, PhD

Context Depression and dementia are common in older adults and often co-occur, but it is unclear whether depression is an etiologic risk factor for dementia.

Objective To clarify the timing and nature of the association between depression and dementia.

Design We examined depressive symptoms assessed in midlife (1964-1973) and late life (1994-2000) and the risks of dementia, Alzheimer disease (AD), and vascular dementia (VaD) (2003-2009) in a retrospective cohort study. Depressive symptoms were categorized as none, midlife only, late life only, or both. Cox proportional hazards models (age as timescale) adjusted for demographics and medical comorbidities were used to examine depressive symptom category and risk of dementia, AD, or VaD.

Setting Kaiser Permanente Medical Care Program of Northern California.

Participants Thirteen thousand five hundred thirty-five long-term Kaiser Permanente members.

Main Outcome Measure Any medical record diagnosis of dementia or neurology clinic diagnosis of AD or VaD.

Results Subjects had a mean (SD) age of 81.1 (4.5) years in 2003, 57.9% were women, and 24.2% were nonwhite. Depressive symptoms were present in 14.1% of subjects in midlife only, 9.2% in late life only, and 4.2% in both. During 6 years of follow-up, 22.5% were diagnosed with dementia (5.5% with AD and 2.3% with VaD). The adjusted hazard of dementia was increased by approximately 20% for midlife depressive symptoms only (hazard ratio, 1.19 [95% CI, 1.07-1.32]), 70% for late-life symptoms only (1.72 [1.54-1.92]), and 80% for both (1.77 [1.52-2.06]). When we examined AD and VaD separately, subjects with late-life depressive symptoms only had a 2-fold increase in AD risk (hazard ratio, 2.06 [95% CI, 1.67-2.55]), whereas subjects with midlife and late-life symptoms had more than a 3-fold increase in VaD risk (3.51 [2.44-5.05]).

Conclusions Depressive symptoms in midlife or in late life are associated with an increased risk of developing dementia. Depression that begins in late life may be part of the AD prodrome, while recurrent depression may be etiologically associated with increased risk of VaD.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990338, encodeId=df1a199033841, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jun 20 05:50:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816519, encodeId=746718165196d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Oct 06 07:50:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791821, encodeId=e14a1e91821d6, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 15 14:50:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817542, encodeId=97ea181e5425c, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 10 13:50:00 CST 2013, time=2013-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469896, encodeId=479a1469896d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 12 04:50:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990338, encodeId=df1a199033841, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jun 20 05:50:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816519, encodeId=746718165196d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Oct 06 07:50:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791821, encodeId=e14a1e91821d6, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 15 14:50:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817542, encodeId=97ea181e5425c, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 10 13:50:00 CST 2013, time=2013-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469896, encodeId=479a1469896d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 12 04:50:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990338, encodeId=df1a199033841, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jun 20 05:50:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816519, encodeId=746718165196d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Oct 06 07:50:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791821, encodeId=e14a1e91821d6, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 15 14:50:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817542, encodeId=97ea181e5425c, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 10 13:50:00 CST 2013, time=2013-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469896, encodeId=479a1469896d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 12 04:50:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990338, encodeId=df1a199033841, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jun 20 05:50:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816519, encodeId=746718165196d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Oct 06 07:50:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791821, encodeId=e14a1e91821d6, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 15 14:50:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817542, encodeId=97ea181e5425c, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 10 13:50:00 CST 2013, time=2013-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469896, encodeId=479a1469896d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 12 04:50:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1990338, encodeId=df1a199033841, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jun 20 05:50:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816519, encodeId=746718165196d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Oct 06 07:50:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791821, encodeId=e14a1e91821d6, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 15 14:50:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817542, encodeId=97ea181e5425c, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 10 13:50:00 CST 2013, time=2013-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469896, encodeId=479a1469896d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 12 04:50:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]

相关资讯

Contraception:激素类避孕药降低维生素B12 意义不大

3月28日,《避孕》(Contraception)杂志在线发表的一项针对育龄妇女的大规模研究显示,虽然在3年研究期间激素类避孕药可导致血清维生素B12水平下降,但未见其临床意义或对骨密度产生影响。 在该项纵向研究中,德克萨斯大学医学部的Abbey B. Berenson博士及Mahbubur Rahman博士招募了703例年龄16~33岁的女性。要求受试者选择3种避孕方法之一:245例选择口服避

Nat Med:Period 2蛋白的激活减少心脏病发作损害

有大量方法来治疗心脏病发作,如心肺复苏术、阿司匹林等。现在,CU医学院的研究人员发现一种新的治疗方式:强烈光线。 副教授Tobias Eckle博士,说:这项研究表明强烈的光线,甚至只是白天,可能会减轻心脏病发作或患从一个损坏的风险。 对于病人来说,这可能意味着,日光照射医院内,可减少心脏病发作造成的损害。 Eckle 和Holger医师发现称为Period 2的蛋白质在抵御心脏病发作造成的伤

AIM:研究表明力量训练或可预防痴呆症

加拿大不列颠哥伦比亚大学一项研究显示,老年人进行力量训练可能有助改善认知能力,预防痴呆症。相关论文发表于4月23日出版的美国《内科学文献》月刊上。 研究人员研究86名年龄介于70岁至80岁的老年女性。这些人都有中度认知障碍,这意味着她们的记忆力或大脑功能出现一定问题,但还没有严重到影响日常生活的程度。这些人患痴呆症的风险比一般老年人大。 研究人员把这些人分成四组,让她们分别从事力量训练、有氧运

JBC:LINGO-1介导抑制髓鞘形成

脱髓鞘疾病(如多发性硬化)新型治疗方法的主要目标是克服髓鞘再生障碍。LINGO-1是一个跨膜信号蛋白,主要在神经元及少突胶质细胞中表达。研究表明,LINGO-1在髓鞘形成过程中是主要的负调控因子。 Nogo受体复合物能够抑制神经元的生长,而LINGO-1在Nogo受体复合物中是以完整形式存在的。到目前为止,细胞外信号通过LINGO-1介导抑制髓鞘形成的机制还不明确。 近日,来自美国维特制药公司

Malaria Journal:非洲疟原虫遗传突变显示出耐药性

在非洲致命性最强的疟原虫中,科学家已鉴定出遗传突变,这些突变使疟原虫能耐受最强效抗疟药,这表明最好的抗疟武器可能已过时。 青蒿素类药物是广泛应用的最有效的治疗疟疾药物,常与其他药物一起作为以青蒿素为基础的联合治疗(ACTs)使用,这时它最强效,几乎不可能被疟原虫耐受。但是,新研究则表明:疟原虫关键部分突变后能耐受青蒿素甲醚,其中青蒿素甲醚是2种最有效青蒿素中的一种。 在该研究中,研究人员从28

AJHG:科学家发现智力残疾的新基因

成瘾性和精神健康中心研究人员领导的一项研究发现智力残疾的新基因,以及该基因是如何可能影响认知能力,破坏神经元运作的。 科学家博士约翰·文森特和他的团队发现有智障的三姐妹体内中基因NSUN2存在突变,相关研究结果发表在American Journal of Human Genetics杂志上。三姐妹来自一个巴基斯坦家庭, 7个兄弟姐妹中有三个是智力残疾以及肌肉无力、行走困难。 智力残疾又被称为智

Baidu
map
Baidu
map
Baidu
map